NOVO NORDISK INC. for NOVO NORDISK INC.
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Defense DEF
TRICARE pharmacy and labeling provisions in HR 2500 FY2020 National Defense Authorization Act (NDAA)
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAUREN ELIZABETH SEMENIUK | — |
Budget/Appropriations BUD
HR 2584/S 1361 Preventive Health Savings Act (issues related to CBO scoring of preventive health services)
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN BRANTON | — |
| AL LYTTON | — |
| SARAH ELIZABETH NORDSTROM | — |
| LAUREN ELIZABETH SEMENIUK | — |
| AMY WOTRING | — |
Health Issues HCR
Medication affordability and access; general diabetes prevention; S 1948/HR 3709 Chronic Disease Management Act and general issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases; implementation of P.L. 115-80 (H.R. 309/S. 920) Clinical Care Commission Act; S 2199/H.R. 4906 Insulin Price Reduction Act; H.R. 3 Elijah Cummings Lower Drug Costs Now Act; S. 1895 Lower Health Care Costs Act; H.R. 19/S 3129 Lower Costs, More Cures Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN BRANTON | — |
| AL LYTTON | — |
| SARAH ELIZABETH NORDSTROM | — |
| LAUREN ELIZABETH SEMENIUK | — |
| AMY WOTRING | — |
Medicare/Medicaid MMM
H.R. 1530/S. 595 Treat and Reduce Obesity Act; H.R. 1840/S. 814 Expanding Access to DSMT Act (Diabetes Self-Management Training); Medicare Diabetes Prevention Program; issues related to podiatric services; issues related to diabetic vision loss and blindness prevention; CMS coverage of diabetes technologies/services; virtual Medicare Diabetes Prevention Program (DPP) diabetes self-management education; issues related to Medicare Part D; issues related to International Price Indexing (IPI)/reference pricing in Medicare; H.R. 107 related to maximum Medicaid rebates; Medicare Part D Rebate Rule; 6 Protected Classes in Medicare Part D; S.2543 Prescription Drug Pricing Reduction Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN BRANTON | — |
| AL LYTTON | — |
| SARAH ELIZABETH NORDSTROM | — |
| LAUREN ELIZABETH SEMENIUK | — |
| AMY WOTRING | — |
Pharmacy PHA
H.R. 1520 Purple Book Continuity Act of 2019; H.R. 1503 Orange Book Transparency Act of 2019; issues related to importation; issues related to 340B; HR 4244 MAGIC (Market Access for Generic Insulin Competition) Act to provide for a pathway for chemically synthesized insulin to be approved under an abbreviated new drug application submitted under the Federal Food, Drug, and Cosmetic Act)
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN BRANTON | — |
| AL LYTTON | — |
| SARAH ELIZABETH NORDSTROM | — |
| LAUREN ELIZABETH SEMENIUK | — |
Taxation/Internal Revenue Code TAX
Issues related to implementation of P.L. 115-97 Tax Cuts and Jobs Act of 2017
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAUREN ELIZABETH SEMENIUK | — |
Government Issues GOV
Issues related to lobbying disclosure and political participation for US affiliates in H.R. 1 For the People Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN BRANTON | — |
| AL LYTTON | — |
| SARAH ELIZABETH NORDSTROM | — |
| LAUREN ELIZABETH SEMENIUK | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.